Lasofoxifene
As of the edition of 20 October 2026, Lasofoxifene is a small molecule: withdrawn from the market in 2012; acts on ESR1 and ESR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2012
- Kind
- Small molecule
- Withdrawn from market
- 27 February 2012 (in some regions)
- Registered trials
- 9, 0 stopped early
- Disease areas
- Bones, joints and muscles; Cancer; Nutrition and metabolism; Skin and connective tissue; Mental health; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 4 | 2 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ligand Pharmaceuticals | Lead sponsor of trials | 2001 to now |